Payment overview · 2025
General Payments
$531.94
4 reported records · 2 companies
Healthcare provider profile · identity verified
Rong Shen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN FRANCISCO, CA · NPI 1215016175
Verified facts
What the public records show
CMS Open Payments records show Rong Shen, MD received $531.94 in general payments during 2025 across 4 reported records.
ABBVIE INC. accounted for 56.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $299.96 | 56.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $231.98 | 43.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $531.94 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $231.98 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $149.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 25 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
25 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1893 | 606 |
| Losartan Potassium | Losartan Potassium | 1366 | 423 |
| Amlodipine Besylate | Amlodipine Besylate | 688 | 210 |
| Metformin Hcl | Metformin Hcl | 670 | 204 |
| Metoprolol Succinate | Metoprolol Succinate | 660 | 195 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 392 | 172 |
| Tamsulosin Hcl | Tamsulosin Hcl | 319 | 105 |
| Famotidine | Famotidine | 284 | 111 |
| Simvastatin | Simvastatin | 218 | 68 |
| Raloxifene Hcl | Raloxifene Hcl | 217 | 72 |
| Meloxicam | Meloxicam | 215 | 123 |
| Furosemide | Furosemide | 214 | 94 |
| Alendronate Sodium | Alendronate Sodium | 201 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 191 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 176 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 82 |
| Jardiance | Empagliflozin | 170 | 55 |
| Azelastine Hcl | Azelastine Hcl | 165 | 78 |
| Tradjenta | Linagliptin | 156 | 45 |
| Lisinopril | Lisinopril | 151 | 43 |
| Gabapentin | Gabapentin | 147 | 61 |
| Azithromycin | Azithromycin | 144 | 112 |
| Potassium Chloride | Potassium Chloride | 142 | 69 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 139 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 48 |
| Glipizide | Glipizide | 134 | 46 |
| Omeprazole | Omeprazole | 133 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 67 |
| Meclizine Hcl | Meclizine Hcl | 123 | 74 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 122 | 54 |
| Allopurinol | Allopurinol | 120 | 40 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 112 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 46 |
| Eliquis | Apixaban | 103 | 34 |
| Finasteride | Finasteride | 101 | 33 |
| Carvedilol | Carvedilol | 98 | 29 |
| Ketoconazole | Ketoconazole | 98 | 29 |
| Montelukast Sodium | Montelukast Sodium | 95 | 34 |
| Ibuprofen | Ibuprofen | 88 | 53 |
| Spironolactone | Spironolactone | 86 | 30 |
| Januvia | Sitagliptin Phosphate | 85 | 22 |
| Amoxicillin | Amoxicillin | 80 | 43 |
| Mupirocin | Mupirocin | 77 | 48 |
| Benazepril Hcl | Benazepril Hcl | 75 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 22 |
| Donepezil Hcl | Donepezil Hcl | 66 | 29 |
| Atenolol | Atenolol | 63 | 19 |
| Enalapril Maleate | Enalapril Maleate | 62 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 27 |
| Lovastatin | Lovastatin | 60 | 18 |
| Acarbose | Acarbose | 59 | 17 |
| Alcohol Swab | Alcohol Antiseptic Pads | 59 | 39 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 58 | 47 |
| Linzess | Linaclotide | 58 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 20 |
| Fluocinonide | Fluocinonide | 54 | 22 |
| Cephalexin | Cephalexin | 52 | 21 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 51 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | 20 |
| Trazodone Hcl | Trazodone Hcl | 48 | 23 |
| Hydrocortisone | Hydrocortisone | 47 | 30 |
| Metformin Hcl Er | Metformin Hcl | 45 | 13 |
| Valsartan | Valsartan | 44 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 12 |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Colchicine | Colchicine | 36 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 16 |
| Loperamide | Loperamide Hcl | 34 | 19 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 16 |
| Telmisartan | Telmisartan | 32 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 28 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Nateglinide | Nateglinide | 26 | suppressed |
| Proctozone-Hc | Hydrocortisone | 26 | 14 |
| Creon | Lipase/Protease/Amylase | 25 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Lorazepam | Lorazepam | 23 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 21 | 12 |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Ciclopirox | Ciclopirox | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Entecavir | Entecavir | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ofloxacin | Ofloxacin | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $531.94 · 4 records | ABBVIE INC. | AREXVY, CREON, LINZESS | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error